Objective: The M.D. Anderson Symptom Inventory (MDASI) is a brief assessment of the severity and impact of cancer-related symptoms. The purpose of this study was the translation and validation of the questionnaire in Greek (G-MDASI). Methods: The translation and validation of the assessment took place at a Pain Relief and Palliative Care Unit. The final validation sample included 150 cancer patients (61 males, 89 females, age range 31–88 years, mean age 63.32). The patients completed the questionnaires at the outpatient clinic. Assessing the validity and reliability constituted the actual validation of the G-MDASI. Results: The item ‘diarrhea’ had a score of 0 in 139 patients and, thus was omitted from the ‘core’ list. Consequently, the core questionnaire consisted of 14 items. Factor analysis resulted in a 3-factor model, in both validation and cross-validation samples. The examination of the sensitivity of the MDASI revealed that there were differences between patients with poor-to-good performance status but no differences were found between patients in different treatment groups. Conclusions: The results showed that the G-MDASI is a reliable and valid measure in Greek cancer patients. It has proved to be a comprehensive symptom assessment tool.

Keywords:
Distress, Greek cancer patients, M.D. Anderson Symptom Inventory, Symptoms
1.
McClement SE, Woodgate RL, Degner L: Symptom distress in adult patients with cancer. Cancer Nurs 1997;20:236–243.
2.
Portenoy RK, Kornblith AB, Wong G, Vlamis V, Lepore JM, Loseth DB, Hakes T, Foley KM, Hoskins WJ: Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 1994;74:907–915.
3.
Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W: Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994;3:183–189.
4.
Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK: Quality of life and survival: The role of multidimensional symptom assessment. Cancer 1998;83:173–179.
5.
Jenkins CA, Taube AW, Turner K, Hanson J, Bruera E: Initial demographic, symptom and medication profiles in patients admitted in continuing palliative care units. J Pain Symptom Manage 1998;16:163–170.
6.
McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1978;1:373–378.
7.
Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kenemy N, Norton L, Scher H: The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30A:1326–1336.
8.
de Haes JC, van Knippenberg FC, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62:1034–1038.
9.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1994;7:6–9.
10.
Williams PD, Ducey KA, Sears AM, Williams AR, Tobin-Rumelhart SE, Bunde P: Treatment type and symptom severity among oncology patients by self-report. Int J Nurs Stud 2001;38:359–367.
11.
Meuser T, Pietruck C, Radbruch L, Stute P, Lehman KA, Grond S: Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247–257.
12.
Kleinmann A, Eisenberg L, Good B: Culture, illness and care: Clinical lessons from anthropologic and cross-cultural research. Ann Intern Med 1978;88:251–258.
13.
Payer L: Medicine and Culture. New York, Holt, 1998.
14.
Bullinger M, Anderson R, Cella D, Aaronson N: Developing and evaluating cross-cultural instruments: From minimum requirements to optimal models. Qual Life Res 1993;2:451–459.
15.
Mystakidou K, Tsilika E, Parpa E, Kalaidopoulou O, Smyrniotis V, Vlahos L: The EORTC Core Quality of Life Questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: Validity and reliability in a Hellenic sample. Int J Cancer 2001;94:135–139.
16.
Mystakidou K, Mendoza T, Tsilika E, Befon S, Parpa E, Bellos G, Vlahos L, Cleeland C: Greek Brief Pain Inventory: Validation and utility in cancer pain. Oncology 2001;60:35–42.
17.
Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA: Assessment of cancer pain, a prospective evaluation in 2266 cancer patients referred to a pain clinic. Pain 1996;64:107–114.
18.
World Health Organization: Cancer Pain Relief, ed 2 (with a Guide to Opioid Availability). Geneva, WHO, 1996.
19.
Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA: Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain 1995;63:65–76.
20.
Zech D, Schug SA, Grond S: Therapiekompendium Tumorschmerz und Symptomkontrolle, ed 2. Erlangen, Perimed, 1988.
21.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC: Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 2000;89:1634–1646.
22.
Aldenderfer MS, Blashfield RK: Cluster Analysis. Beverly Hills, Sage, 1984.
23.
Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrica 1951;16:297.
24.
Nunnally JC: Psychometric Theory, ed 2. New York, McGraw-Hill, 1978.
25.
Harman HH: Modern Factor Analysis, ed 2. Chicago, University of Chicago Press, 1967.
26.
Gorsuch RL: Factor Analysis. Philadelphia, Saunders, 1974.
27.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
28.
Dodd M: Managing Side Effects of Chemotherapy and Radiation Therapy. Norwalk, Appleton & Lange, 1994.
29.
Rhodes V, McDaniel R, Johnson M: Patient education: Self-care guides. Semin Oncol Nurs 1995;11:298–304.
30.
Orem D: Nursing: Concepts of Practice, ed 2. New York, McGraw-Hill, 1980.
31.
Bruera E, Pereira J: Recent developments in palliative cancer care. Acta Oncol 1998;37:749–757.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.